Lilly, Boehringer celebrate Synjardy's FDA nod; Bayer moves heart failure med into Phase III;

> Eli Lilly & Co. ($LLY) and Boehringer Ingelheim's new diabetes combo med Synjardy--which combines the active ingredient in the SGLT2 drug Jardiance with metformin--won U.S. approval, becoming the third empagliflozin product blessed by the FDA. Release

> Bayer is advancing its new heart failure drug into Phase III testing after the drug, finerenone, posted a "striking" reduction in deaths in a mid-stage trial. Report

> Allergan ($AGN) wrapped up its $560-million-plus deal for Naurex and its two antidepressants, which recently posted promising mid-stage data. Release

> France's Ipsen said its muscle injection Dysport, a competitor to Allergan's Botox, proved effective and safe at treating upper limb spasticity in adults with neurological disorders. Report

> Endo International ($ENDP) said its Xiaflex drug for Dupuytren's Contracture now has official pricing in Japan and is set for a mid-September launch there. Release

And Finally... Frequent use of antibiotics might boost the risk of Type 2 diabetes, a study found. Report

Suggested Articles

Horizon Therapeutics is preparing for the potential launch of inflammatory eye drug teprotumumab with team building.

Sanofi’s chief digital officer isn’t surprised to see CDOs popping up across Big Pharma. But they have to earn their keep, he says.

In a head-to-head against Bayer's Nexavar, Opdivo failed to significantly extend patients' lives in newly diagnosed liver cancer patients.